Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acute renal failure in newborn. Case presentation].

O Brumariu1, Mihaela Munteanu, Florentina Cucer

  • 1Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi, Facultatea de Medicină, Clinica a IV-a Pediatrie.

Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi
|February 4, 2005
PubMed
Summary

Acute renal failure affects 6-8% of newborns. This case study highlights peritoneal dialysis as a treatment for neonatal kidney injury caused by severe umbilical cord bleeding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

BMC cancer·2024
Same author

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

BMC cancer·2024
Same author

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

BMC cancer·2024
Same author

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

BMC cancer·2024
Same author

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

BMC cancer·2024
Same author

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.

Investigational new drugs·2024

Area of Science:

  • Neonatology
  • Pediatric Nephrology
  • Critical Care Medicine

Background:

  • Acute kidney injury (AKI) is a significant concern in newborns, affecting 6-8% of this population.
  • While various causes exist, renal cortical necrosis secondary to perinatal asphyxia or anemia are recognized but uncommon etiologies.
  • A systematic diagnostic approach aids in identifying the cause of AKI in most neonates.

Observation:

  • This report details the first experience using peritoneal dialysis in a newborn with severe renal injury.
  • The renal injury was a direct consequence of significant bleeding from the umbilical cord.
  • The neonate required intervention due to the severity of the bleeding-induced kidney damage.

Findings:

  • Peritoneal dialysis was successfully employed as a therapeutic modality for neonatal renal injury.

Related Experiment Videos

  • The treatment addressed the acute renal failure resulting from severe umbilical cord hemorrhage.
  • This case demonstrates the feasibility and potential efficacy of peritoneal dialysis in this specific neonatal context.

    • Implications:

    • This case suggests peritoneal dialysis as a viable treatment option for neonatal acute kidney injury stemming from severe umbilical cord bleeding.
    • The findings may encourage further investigation into the role of peritoneal dialysis in managing specific types of neonatal renal compromise.
    • Establishing effective treatments for neonatal AKI is crucial for improving outcomes in critically ill newborns.